![](https://library.celltelligence.com/wp-content/uploads/2021/01/EMA_Announcement.png)
$0
Could Yescarta Receive a CHMP Positive Opinion for ≥4L FL This Week? Yescarta’s Evaluation for 2L DLBCL Listed in February’s CHMP Agenda
On Monday, February 21, the CHMP agenda for February was released. Of note, Yescarta’s (Gilead /Kite’s CD19 CAR-T) Type II Variations in ≥4L FL and 2L DLBCL are listed under ‘Type II Variations – Opinions or Requests for Supplementary Information’. No other cell therapy-related updates were observed. Below, Celltelligence provides insights on the potential EU approval timeline for Yescarta in ≥4L FL.